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Restenosis limits the long-term beneficial effects of percutane- 
ous transluminal coronary angioplasty and related procedures 
(1). The importance of diabetes as a consistent clinical predic- 
tor for restenosis after angioplasty has been demonstrated in 
several studies. The initial report from the National Heart, 
Lung, and Blood lnstitute Angioplasty Registry t2) indicated 
that the angiographic restenosis rate in diabetic patients was 
47% compared with 32% in nondiabetic patients. Subsequent 
studies have reported restenosis rates of 49% to 71% among 
diabetic patients (3-9). 
New angioplasty devices failed to make any major impact 
on the rcstenosis rate among diabetic patients. Diabetes is 
associated with a twofold increase in recurrent clinical events 
after directional coronary atherectomy (10). Likewise, diabetic 
patients have higher restenosis rates after stent placement (I 1) 
and after cxcimer laser angioplasty (12). 
Restenosis is viewed as an intraluminal growth process after 
an arterial injury (see below), and risk factors for restenosis are 
likely to be risk factors for this growth process. In contrast to 
diabetes, other traditional risk factors for atherosclerosis, such 
as male gender, hypertension, hypercholesterolemia and con- 
tinued smoking after angioplasty, have been reported as risk 
factors only inconsistently (1,3,7.8). In attempting to predict 
restenosis from clinical variables. Weintraub et al. (3) con- 
cluded that “the problem is that each of the clinical variables 
is a correlate without a clear relation to the underlying 
pathophriological process.” The intent of this review is to 
examine some of the putative mechanisms involved in the 
resterross process in light of pathophysiologic events currently 
known to occur in the diabetic state. 
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Pathophysiologic Mechanisms of Restenosis 
in Relation to Diabetes 
The complex pathophysiologic events leading to restenosis 
after balloon injury involve endothelial denudation; platelet 
deposition with mural thrombosis; vascular smooth muscle ceil 
proliferation and migration; and extracellular matrix synthesis 
(13-17). Intimal smooth muscle cell hyperplasia is the predom- 
inant histologic finding in restenotic lesions (18). A fundamen- 
tal element in the development of intimal hyperplasia is the 
transformation of smooth muscle cells from a contractile to a 
proliferative. secretory phenotype. The restenosis process is 
initiated when balloon inflation causes endothelial denudation 
and deep vessel injury. Tine exposure of subendothelial ele- 
ments initiates platelet adhesion and activation. Activated 
platelets at the site of injury secrete growth factors that release 
smooth muscle cells from growth inhibition and induce their 
proliferation and subsequent migration from the media to the 
intima (15,17). Smooth muscle cell proliferation continues 
beyond the phase of platelet deposition (14). Activated smooth 
muscle cells themselves secrete growth factors that can act on 
surrounding cells and help to sustain proliferation and migra- 
tion (19). The proliferative response becomes quiescent sev- 
eral months after intervention. 
A second fundamental element of restenosis is the produc- 
tion and secretion of extracellular matrix by smooth muscle 
cells that have migrated into the injured intimal zone (17). The 
neointima is generally hypocellular, composed predominantly 
of extracellular matrix material thdt forms the bulk of neoin- 
timal growth (13,16). 
Although vessel recoil may also contribu:e to loss of lumen, 
the markedly increased restenosis rate seen in diabetic patients 
after stent placement (11) underscores the role oi enhanced 
smooth muscle cell proliferation as the major mechanism for 
restenosis in these patients, because coronary artery stenting 
provides a rigid endovascular lattice that prevents both elastic 
recoil and vascular spasm at the treated site (11). 
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Figwe 1. Proposed model for accelerated vascular lesion formation in 
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libmbhgmwtbtactor,ECM=exlraceUularmatrix.EDRF=endotbe- 
lium&kd relax@ factcq ET-I = en&Win-l; IGF-I = ins.~Iin-like 
gmwb f’aaar-1; Kil, = pros&q&~; ‘R3F-a = nan&mkng growth 
f-&or-w TCF+ = km&ming growth f&%x-beta; TxA, = throm- 
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In the diabetic state, several mechanisms combine to pro- 
mote the various processes that constitute the biology of the 
restenosis process (Fig. 1). In the following section, these 
mechanisms are discussed. 
Endothelial Dysfunction 
The removal of the endothelial lining by balloon injury and 
the endothelial dysfunction that persists during endothelial 
regeneration both amtribute to the rcstenosis process by 
promoting thrombosis, vasoamstriction and smooth muscle 
cell growth. The amount of endothelial denudation appears to 
correlate with the degree of later neointimal thickness (20). 
Furthermore, endothelial layer regeneration after vascular 
injury is critical in determining the eventual lesion formation 
(1521). Indeed, intimal hyperplasia is greater in areas where 
end&&l regeneration occurred last (14). 
The integrity and function of the endothelial cell layer 
are profoundly altered in diabetic animals and humans (Table 
1). The best-characterized endothelial abnormality is im- 
paired endotheliumdependent relaxation (Z-24). impaired 
endotheliumdependent relaxation can be induced by short 
exposure (several hours) to high glucose concentration (2225) 
and occurs in ditferent vascular beds including the coronary 
arteries (26). 
Diabetes can impair endotbelium-dependent relaxation by 
at least hvo mechanisms: 1) Advanced glycosylation end prod- 
ucts (see later) have been shown to rapidly inactivate 
endotheliumderived relaxing h tar in vitro through a direct 
Tabk 1. Effects of Endothelial qsfunction in Diabetes MeWus 
on Restenosis 
DiabeteAnduccd 
End&Aial Dysruncrion 
Inacriva~ion of EDRF 
Reduced PC& ythesis 
locreased ET-I pr&ction 
bllpaidenddheiial 
regeneration 
PosyMe Pmnmbg ESecn on Restenosb 
Vasocwstriction: 10~ of antiproliferative 
activity of EDRF: &eared platekt 
adhesion aDd WgdtiOll 
VasoawstricIioa: increacd platelet 
agglqatioo 
Vasaoastriclioa; incnxwd SMC pmiiferati-on 
P&mgedexpawre0fSMCl0~ 
mitogem; prolonged iaterdclioo of piarelet 
withveoelwau 
EDRF = endotkliamderived relaxing factor. ET-I = cndothelin-I: 
PGI, = pmstacydin: ShlC = smooth mu& cell. 
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chemical reaction (273). 2) Increased generation of oxygen 
free radicak, which occurs in diabetes (2229) also inactivates 
endotheliumderived relaxing factor before it can exert its 
action on smooth muscle celk (2530). Vasospasm at the 
dilated coronary artery segment occurs commonly and may 
contribute to the early reduction in gain and promote clot 
formation (31). However, the loss of endotheliumderived 
relaxing factor has a profound effect on the arterial wall 
beyond the tendency to vasospasm because it inhibits both 
platelet aggregation and smooth muscle cell proliferation 
(32-34). 
P~~~tacyclin is another endothelial vasodilator that ako 
inhibits platelet aggregation and adhesion to the endothelium 
(34). Diabetes-induced alterations in prostaglandin metabo- 
lism result in a reversible decrease in prostacyclin production 
by endothelial celk (3536). 
Endothelin-I is a potent natural vasoconshictor synthesized 
and secreted from endothelial cells; it is also a mitogen for 
smooth muscle cells (32). Plasma endothelin-1 concentrations 
are signihcantly increased in diabetic patients (37). Physiologic 
concentrations of insulin enhance the transcription rate and 
secretion of endothelin-1 mRNA in endothelial cells (38,39). 
Hence, the hyperinsulinemic state that characterizes type II 
diabetes may result in a continual stimulus for endothelin-1 
production and secretion. 
In addition to the impaired function of endothelial celk, 
diabetes affects their migration and proliferation. Human 
vascular endothelial cell replication in culture is inhibited in 
the presence of high glucose concentrations (40.41). In spon- 
taneously diabetic rats, the regeneration of the endothelium 
after catheter deendothelialization is slower than control rats, 
resulting in prolonged interaction of platelets with the de- 
nuded vessel and, subsequently, in greater neointimal prolif- 
eration (42). 
The impaired ability of endothelial cells to regenerate after 
balloon injury along with the functional alterations in local 
production of vasodilators, antiaggregants and antiprolifera- 
tive molecules that occur in diabetes are likely to have a 
considerable effect on the restenosis process by decreasing 
reendothelialization. increasing the propensity to thrombosis 
and reducing the capacity of endothelial cells to produce the 
appropriate growth inhibitors for smooth muscle cells. 
Platelet Aggregation and 
Thrombus Formation 
The earliest finding after balloon dilation is platelet depo- 
sition along the denuded surface. often with subsequent 
thrombus formation. The importance of thrombus formation 
in the restenosis process is emphasized by the observation that 
severe thrombocytopenia induced by antiplatelet antibodies 
inhibits neointimal accumulation after vascular injury (43). 
Similarly, antibodies directed against the platelet IIb/IIIa 
receptor integrin have been shown to significantly decrease the 
clinical restenosk rate (44). 
Platelets that adhere and aggregate at sites of endothelial 
disruption release several prothrombotic, rasoconstrictive and 
growth-promoting mediators (Table 2) that stimulate neointi- 
mal growth (154546) and have sustained biilogical effects on 
myointimal hyperplasia long alter platelet deposition and 
thrombosis have resolved (31). 
In diabetic patients, elevated fractions of activated platelets 
circulate in the absence of clinically detectable vascular lesions 
(47). In addition, platelets from diabetic subjects exhibit an 
enhanced adhesiveness, and hyperaggregabihty in response to 
various agonists, including epinephrine, co&en, arach&& 
acid and thrombin (48-50). Platelet extracts from diabetic 
patients have been shown to have signScantly greater growth- 
promoting potential for smooth muscle celk in ctdture than 
rhose from control subjects. However, after intensive insuhn 
therapy, the platelet growth activity of these patients sign& 
candy declined and became similar to control levek (51). 
Thromboxane A, a potent platelet activator and vasocon- 
strictor, is synthesized in platelets during platelet activation. 
Increased thromboxane A2 concentrations at sites of endothe- 
lial injury facilitate platelet aggregation and contribute to the 
neointimal proliferative response (52). Enhanced activity of 
the platelet arachidonic acid pathway with increased throm- 
boxane A2 synthesis occurs in diabetic subjects (53). There is a 
significant correlation between thromboxane AZ produaion 
and fasting plasma glucose or hemoglobin A,,-, and normal 
thromboxane AZ production can be restored by strict glycemic 
control (4954). 
The ahnormal platelet function in diabetes is reflected in 
platelet interaction with deendothelialized vessek after bal- 
loon injury. Platelet accumulation on the injured aorta of 
diabetic rats is prolonged compared with control rats (42). 
resulting in a thicker intima with a greater number of layers of 
smooth muscle cells m diabetic rats (42). 
Other abnormalities in the coagulation system in diabetic 
patients that enhance platelet aggregation and thrombus for- 
mation includ elevated fibrinogen levek (55,56), increased 
Factor VII levels in response to hyperglycemia (5657) and a 
decrease in the biological activity of antithrombin III as a 
result of nonenzymatic glycosylation of the lysine residue that 
binds it to its natural cofactor, heparin (56). In addition, a 
characteristic feature of insulin resistance and hyperinsuline- 
mIa is reduced plasma fibtinolytic activity caused by increased 
plasminogen activator inhibitor I activity (5859). In vitro 
studies (60) have shown that proinsulin, a precursor of insulin, 
augments plasminogen activator inhibitor 1 gene expression in 
hepatocytes, resulting in an increased synthesis by the liver, 
which is the primary source >I this molecule in plasma. 
III hummar),, alterations m hemostatic mechanisms in the 
diabetic state can lead to further recruitment of platelets and 
mural thrombus formation through hypersensitivity of platelets 
to agonists at sites of vessel injury, decreased effectiveness of 
the inhibited thrombolytic system and elevated clotting factor 
levels. 
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Tabk 2 Gmwth Faders Imolved ia Patbogznesis of RestenoW 
GlWtbFXtOrand 
same PC&UtidR&inRestenais E&t of Di&cks 
PDGF 
Platekt afp@wdq Wmtpcte.az fador” for SMCs WCs qres more PDGF beta- 
SMCsddtelium recqaor mRN& AGE-momqe 
iIItcradioole5UttSinPDGF 
Tkaie 
IGF-I 
SMCS codrHbclium “Rogrrssioo factor” far PDGF-mechated Highinsulinkuekstim&tetbe 
llggydangar(h;~tith IGF-I reapor, &din enlmnccs 
IGF-I eqnc&m 
bFGF 
shK$-lium Fbwerfulmitoge&a&ityforsMCsmd wglncose amambatiotn 
Ecs; anti&ffiF an&dies i&bit SMC incmse bFGF mRNA kvek 
DNA~ptb&afterbrOooo~ 
TGF&tat 
Phtekt-alpha Bawla; h4oddates-lhllalnmtrkpodudion; che~inbype~and 
etbr%tkcmSm po@eotcbaucMkfactcufor~and inpremuofAGEs 
EDRF 
Enddbelium LosofEDJtFilldwSptatek1~tioo, lnadivated ty AGES ami oxygen 
-athiallowssMc fnxdicakthatanmmlateat 
proliferation amktated rate in diabetes 
Er 
EIKbtbelium Mitogen for WC.5 -sccntionin 
hype-olic states 
HS 
Endculeliom; sMcs lnhkitiror of SMC proliferation -synchesis;iaTeared 
tUtUWC1 
*Data from references lrJ7324562-67,76n,77.79BIBL tHin both grawtb-pomotisg and grod&hibitory prop 
ertksAGE=advancd&aqMonendpnxb@bFGF=baricfibmblast~taaos;EC=e&tbelialce.U: 
EDW = ettbtbdiumderivcd reming factw, ET-1 = e&tbelia-1; HS = hepatan sutt%te; IGF-1 = india-like growth 
f-&or-l; PDGF = platektdcrived grwth facts, WC = smooth mude cell; TGF-beta = vansforming growth factor- 
beta. 
Dysregulatim of Growth Factor Expression 
The metabolic alterations associated with diabetes darn 
promote restenosis through unique alterations in local growth 
factor production and action, which in turn may induce prolif- 
eration of smooth muscle cells and extracellular matrix synthe- 
sis (Table 2). Alterations in growth factor expression have been 
implicated in the pathogenesis of proliferative diabetic reti- 
nopathy as well as in the mesangial cell proliferation and 
excessive matrix deposition that characterize diabetic nephrop 
athy (61,62). Because many of these mitogenic mediators are 
overexpressed by vascular smooth muscle cells and endothelial 
cells in diabetic patients, it is reasonable to assume that they 
contriiute to restenosis. 
Platelet-Derived Growth Factor and 
Insulin-Like Growth Factor-i 
Platelet-derived growth factor is a “competence factor” for 
smoothmusdecellsinthatitenablestheceUtomclve~mthe 
quiescent (i.e., contractUe) phenotype into the active phase of 
replication (63). Progx&n into actual replication requires a 
second class of growth fact- termed “ptogre&on facto-” 
which trigger “competence” factor-primed cells to prohferate. 
One of the progression factors for plateletderived growth 
factor-mediated cell grmvth is insulin-like growth factor-l 
(64j. Higher concentrations of insulin-like growth factor-l 
have been demonstrated in smooth muscle cells of the syn- 
thetic phenotype from restenotic human coronary atherectomy 
plaques compared with smooth muscle cells of the contractile 
phemv (65). 
Smooth muscle cells from diabetic rats grow faster than 
normal smcoth musde cells in response to platelet-derived 
growth factor (66) and after balloon catheter injury (67). These 
cells egress more platelet-derived growth factor-beta- 
receptor mRNA, which is typically expressed on the contractile 
phenotype of smooth muscle cells (66,67). llms, vascular 
smooth musc!e cells may be more sensitive to the growth 
stimulatory action of platelet-derived growth factor in the 
presence of diabetes. 
Alterations in insulin-like growth factor-l regulation that 
lead to increased expression and elevated tissue level of this 
growth factor have been implicated in the pathogenesis of 
renal hypertrophy in diabetic nephro@ry (6168). Similarly, 
insulin-like growth factor-l may be imolved in the pathogen- 
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esis of accelerated diabetic retinopathy (69) as patients with 
diabetic retinopathy have elevated insulin-like growth factor-l 
levels in the vitreous humor (70). The role of insulin-like 
growth factor-l in the development of macrovascular lesions is 
less clear. 
Insulin as a Growth Factor for Vascular 
Smooth Muscle Cells 
Physiologic concentrations of insulin are known to stimu- 
late proliferation of cultured smooth muscle cells and fibro- 
blasts (71,72). Although insulin itself is a poor mitogen (73). it 
can potentiate the expression of the more potent mitogen 
insulin-like growth factor-l (74,75). Thus, in the presence of 
insulin resistance, where the metabolic action of insulin is 
ineffective, the proliferative response to hyperinsulinemia may 
still occur. 
Transforming Growth Factor-Beta 
Transforming growth factor-beta is the most important 
growth factor regulating the extracellular matrix production 
that characterizes intimal hyperplasia in its advanced stages 
(13,76,77). In the rat carotid artery injury model, administra- 
tion of neutralizing antitransforming growth factor-beta anti- 
bodies reduces matrix accumulation in intimal lesions (78). 
Transforming growth factor-beta expression has been investi- 
gated in diabetes in relation to diabetic nephropathy because 
one of its dominant features is the expansion of extracellular 
matrix in the mesangial areas. In animal models of diabetes, 
the expression of transforming growth factor-beta in the 
kidney increases within a few uays of the appearance of 
hyperglycemia (6279) in association with active production of 
matrix components in the glomeruli (62). The increase in 
transforming growth factor-beta mRNA and protein in dia- 
betic rats can be attenuated with insulin treatment (62). 
Recently, increased transforming growth factor-beta mRNA 
and protein were demonstrated in kidneys of patients with 
advanced diabetic nephropathy (62). 
The expansion of the extracellular matrix in diabetic ne- 
phropathy bears many similarities to the extracellular matrix 
accumulation that results from arterial injury. In this context, it 
should be emphasized that mesangial cells act as specialized 
contractile smooth muscle cells that produce extracellular 
matrix components (80). Termination of extracellular matrix 
deposition is essential to avoid excessive neointimal growth 
after balloon catheter injury. Thus, failure to regulate or 
terminate transforming growth factor-beta expression in the 
presence of diabetes may potentially lea,l to excessive matrix 
deposition with greater encroachment on the arterial lumen. 
Other Growth Factors 
Hyperglycemia affects the expression of several other 
growth factors such as basic fibroblast growth factor and 
transforming growth factor-alpha (81). Smooth muscle cells 
exposed to high glucose concentrations increase their basic 
fib&last growth factor mRNA levels (81). Basic fib&last 
growth factor is a potent mitogen for smooth muscle celk and 
may be involved in restenosis, because rats treated with 
blocking antibodies to basic tibrobkst growth factor have 
decreased smooth muscle cell proliferation after balloon cath- 
eter injury (82). Transforming growth factor-alpha k known to 
be expressed in smooth muscle and endothelial cells (45.81). 
llms, when overexpressed in the presence of hyperglycemia, it 
may promote restenosis. 
Increased myointimal proliferation and matrix deposition in 
diabetic patients may be a consequence of altered production 
of local or circulating growth factors and/or modulations in the 
response to these factors. The cellular events that lead to 
altered regulation of growth factor expression in diabetes are 
largety unkmnvn. Regulation of growth factor expression by 
glucose seems to occur at the tramcriptional level and may be 
mediated by one of its intracellular metabolites (81). Regard- 
less of the mechanism involved, the presence of diabetes can 
selectively alter gene expression in smooth muscle cells, lead- 
ing to dysregulation of growth factors that are known media- 
tors of the restenosis process. 
Abnormal Elxtracellular Matrix 
Composition-Role of Heparan Sulfate 
The extracellular matrix regulates cell migration prolifera- 
tion and matrix production by means of cytoskeletal signals 
and by posttranslational control of growth factors (83). An 
important factor in the release from growth inhiiition follow- 
ing balloon injury is the loss of inhibitory control of the 
surrounding proteoglycan matrix. Matrix-associated heparan 
sulfate is a potent inhibitor of smooth muscle cell proliferation 
and plays an important role in the regulation of smooth muscle 
cell growth in injured arteries (13,17&t). After balloon injury, 
endoth&d hudatioir, disruption of the prOieO&Giil matrix 
of the medial layers and activated platelet release of endogly- 
cosidases that cleave heparan sulfate from the surface of 
smooth muscle cells all lead to the loss of the inhtbitory effect 
of heparan sulfate. In addition, the removal of heparan sulfate 
renders cells receptive to growth factors and contributes to 
their phrnotypic modulation (13,14,17). 
Hy-rerglycemia induces an increase in selected matrix gene 
transcription that persists for weeks after restoration of nor- 
moglycemia in vivo (85). This results in an incraed synthesis 
of extracellular matrix components such as collagen type IV, 
libronectin and laminin. Abnormalities in the synthesis and 
metabolism of heparan sulfate have been repeatedly reported 
in association with both experimental and human diabetes 
(79,86,87). The density of heparan sulfate has been shown to 
be significantly reduced in the glomerular basement membrane 
of patients with diabetic nephropathy (79,86,87). Hyperglyce- 
mia causes a decrease in the de novo synthesis of heparan 
sulfate (88) probably because of decreased activity of the 
JAcrVd.27.Na3 
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enzyme Mdeacetylase, which plays a key role in its biosynthesis 
(89). Interestit@, the administration of protamine as part of 
commmly used insulin preparations exacerbates smooth mus- 
de cd proliferative lesions after balloon injury in rats and 
interferes with the grrxtth inhiitory effects of heparin in 
cuhltreandhvivo(90). 
In summuy, diminution of matrix-bound heparan sulfate 
can mnlt in loss of tonic growth inhiition and facilitate 
smooth muscle cell proliferation. Hyperglycemia-induced aug- 
mentation in matrix component production may increase neo 
iotimal VohJme (F-Ii. 1). 
Role of Advmced Glycosylatim End 
Products in Restenosis 
Advaaad glycqlation end products are a heterogeneous 
clas of mmenaymatically gtycosylated adducts of proteins or 
Iipidsthata#xtlmuIateinvasallartissueswithagingandatan 
accderated rate in diabetes The degree of nonenzymatic 
glyaqlation is determined mainly by tbe glucose concentra- 
tion and time of exposure (91-94). Advaxed Hation end 
prodU&areabmldantinmosttissu~aod!hlidsand,through 
the induct& of qtokines and growth-promoting mediators, 
may partic&te in tissue remodeling (91-94). Advanced glyco- 
sylation is implicated in the initiation and acceleration of 
multiple organ damage in diabetic patients, including macro- 
wscular disease, nephropathy, and neuropathy (91~%), and 
mayalsopromotetberestenosisprocess. 
Advamd gjpsylation end pmducts interact with vessel 
wall ceUular components through a specitic receptor system 
present on various cell types, including monocyt~ endothelial 
cells and smooth muscle cells (94,%,97). Monocyte receptor- 
mediated interaction with advanced glyco@ation end products 
tesultsintheprodWionofmediatorssuchastumornecrosis 
factor-alpha, plateletderived growth factor and insulin-like 
growth factor-l (98-100). 
Momxytes and lymphocjtes are known io migrate into the 
tbrombtts that forms in the balloon injury site. This cellular 
infiltrate may be an abundant source of growth factors and 
chemonztant substances, facilitating and sustaining further 
cellular recruitment and smooth muscle cell growth (15-17). 
The presence of advanced glycosylation end products in the 
exposed vessel wall wutld be expected to promote the migra- 
tion of intlammatoty cells into the lesion with tbe subsequent 
release of growth-promoting cytokines. Furthermore, spccitic 
binding of glycosylated proteins by cultured rat smooth muscle 
cells is associated with increased cellular proliferation (9394) 
that is likely to be cytokine or growth factor mediated. 
Finally, advanced glycosylation end products influence the 
expression of selected extracelluhu matrix genes (e.g.. collagen 
type IV, laminin) as well a5 transforming grcwth factor-beta 
(101). Advanced glycosylation also alters the functional prop 
erties of several important matrix constituents Glyccsylation 
of matrix components such as collagen IV, laminin and 
vitronectinwiUdecreasebindingofanionic heparan sulfate, 
leading to greater turnover of heparan sulfate (92,102). Gly- 
cosylation of the extracellular matrix also alters the normal 
interactions of transmembranc integrin receptors with their 
specific matrix ligands. For example, moditicdtion of the 
cell-binding domains of type Iv collagen causes decreased 
ertdotbelial cell adhesion (92JE). 
!3tuwmy. Advamxdglya@ationendproductscanmedi- 
ate intlammatory cell recruitment and activation, stimulation 
of smooth muscle cell proliferation and abnormal matrix 
production, all of which can promote the restenosis process 
conclusions 
Diabetes iniluertces various cellular events involved in the 
vessel mspomie to injury (Fig. 1). lbe same mechanisms can 
potentially play a role in the intimal proliferation that causes 
luminal loss in tire hrst years after bypass surgery with venous 
cotlduit (103). 
An important question is whether the restenosis rate can be 
reduced in diabetic patients. Pharmaco@ic manipulations for 
the prevention of restenosis are based on insights into the 
pathophy&logic me&a&m of restenosis and include growth 
factor inhibitors (e.g, Wapidil) (17) new antithrombotic agents 
(44), antiinflammatory agents and gene therapy (14.17). How- 
ever, it may be posr&le to use simpler measures in diabetic 
patients. Many of the potential mechanisms promoting resten- 
osis in diabetic patients are related to elevated glucose or 
insulin levels, or both Moreover, the majority of these abnor- 
malities are reverst&le on improved glycemic control. There- 
fore, we anticipate that rigorous glycemic control may reduce 
the restenosis rate in diabetic patients. However, some of the 
alteration induced by the metabolic abnormalities of the 
diabetic state may not be readily reversible. For example, 
hyperglycemia-induced gene transcription may persist for 
weeks after restoration of normog&emia in vivo (85). This 
phenomenon has been termed hyperglycemic memory and 
may reflect irreversible imraceUular and extracellular effects of 
hyperglycemia (&5,102). In addition, normoglycemia is fre- 
quently achieved at the price nf peripheral hyperinsulinemia. 
Clinical trials are needed to evaluate the impact of tight 
glycemic control on restenosis rates among diabetic patients. 
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